Compare WOLF & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WOLF | RAPP |
|---|---|---|
| Founded | 1987 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2025 | 2024 |
| Metric | WOLF | RAPP |
|---|---|---|
| Price | $26.38 | $26.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $25.00 | ★ $64.21 |
| AVG Volume (30 Days) | ★ 3.3M | 1.4M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | $14.87 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $13.49 | $22.06 |
| 52 Week High | $80.82 | $52.93 |
| Indicator | WOLF | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 43.33 |
| Support Level | $23.31 | $22.06 |
| Resistance Level | $26.70 | $31.49 |
| Average True Range (ATR) | 2.23 | 2.26 |
| MACD | 0.19 | 0.45 |
| Stochastic Oscillator | 95.42 | 48.78 |
Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.